Genmab A/S ADS (GMAB) Stock Price

GMABStock

$37.00+20.00%52W

Market Cap$22.75B

P/E23.60x

PEG Ratio4.65

Div yield—

Beta0.68

GMAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)25.85%

Price vs S&P 500 (4W)12.03%

PEG Ratio4.65

VGM Score58.66

P/E Ratio (Annual)23.60x

P/CF (Annual)19.16x

Book Value / Share (Quarterly)$96.96

P/TBV (Annual)4.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)21.97%

Cash Flow / Share (Quarterly)$14.13

Price vs S&P 500 (YTD)11.51%

Gross Margin (TTM)93.03%

Net Profit Margin (TTM)19.08%

EPS (TTM)$12.69

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$12.69

Revenue Growth (5Y)19.19%

EPS (Annual)$15.36

ROI (Annual)8.54%

Gross Margin (Annual)93.60%

Net Profit Margin (5Y Avg)32.29%

Cash / Share (Quarterly)$24.46

P/E Basic Excl Extra (TTM)28.84x

Revenue Growth QoQ (YoY)24.86%

EPS Growth (5Y)6.82%

P/E Normalized (Annual)23.60x

ROA (Last FY)7.48%

Revenue Growth TTM (YoY)22.33%

EBITD / Share (TTM)$17.93

ROE (5Y Avg)17.15%

Operating Margin (TTM)25.95%

Cash Flow / Share (Annual)$18.35

P/B Ratio3.81x

P/B Ratio (Quarterly)2.82x

Net Income / Employee (Annual)$317,900

EV / Revenue (TTM)6.41x

Net Interest Coverage (TTM)15.44x

ROA (TTM)7.04%

EPS Growth QoQ (YoY)-9.41%

EV / EBITDA (TTM)23.57x

EPS Incl Extra (Annual)$15.36

Current Ratio (Annual)2.02x

Quick Ratio (Quarterly)2.37x

3-Month Avg Trading Volume0.12M

52-Week Price Return20.00%

EV / Free Cash Flow (Annual)23.43x

P/E Incl Extra (TTM)28.84x

Revenue / Employee (TTM)$1,363,800

Tangible BV / Share (Quarterly)$65.02

P/S Ratio (Annual)6.11x

Asset Turnover (Annual)0.29x

52-Week High$2603.00

Operating Margin (5Y Avg)34.07%

EPS Excl Extra (Annual)$15.36

CapEx CAGR (5Y)3.22%

Tangible BV CAGR (5Y)10.66%

26-Week Price Return35.76%

Quick Ratio (Annual)2.01x

13-Week Price Return35.46%

Total Debt / Equity (Annual)0.93x

Current Ratio (Quarterly)2.46x

Enterprise Value$26.49B

Revenue / Share Growth (5Y)20.38%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)14.61%

Revenue / Employee (Annual)$1,228,100

Inventory Turnover (Annual)17.89x

Pretax Margin (Annual)32.37%

Cash / Share (Annual)$27.83

3-Month Return Std Dev31.24%

Gross Margin (5Y Avg)97.53%

Net Income / Employee (TTM)$260,200

EBITDA CAGR (5Y)2.32%

EBITDA Interim CAGR (5Y)24.81%

ROE (Last FY)16.47%

Net Interest Coverage (Annual)2.98x

EPS Basic Excl Extra (Annual)$15.36

P/FCF (TTM)26.12x

Receivables Turnover (TTM)3.97x

EV / Free Cash Flow (TTM)30.52x

Total Debt / Equity (Quarterly)0.89x

EPS Incl Extra (TTM)$12.69

Receivables Turnover (Annual)3.67x

ROI (TTM)7.99%

P/S Ratio (TTM)5.50x

Pretax Margin (5Y Avg)40.72%

Revenue / Share (Annual)$59.34

Tangible BV / Share (Annual)$53.22

Forward P/E22.36x

Free OCF CAGR (5Y)3.84%

Price vs S&P 500 (52W)4.47%

P/E Ratio (TTM)28.84x

EPS Growth TTM (YoY)-36.40%

Year-to-Date Return23.43%

5-Day Price Return0.60%

EPS Normalized (Annual)$15.36

ROA (5Y Avg)13.54%

Net Profit Margin (Annual)25.89%

Month-to-Date Return6.79%

Cash Flow / Share (TTM)$32.63

EBITD / Share (Annual)$17.85

EPS Growth (3Y)9.58%

Operating Margin (Annual)28.63%

LT Debt / Equity (Annual)0.86x

P/CF (TTM)25.50x

ROI (5Y Avg)15.25%

P/E Excl Extra (TTM)28.84x

LT Debt / Equity (Quarterly)0.81x

EPS Basic Excl Extra (TTM)$12.69

P/TBV (Quarterly)4.65x

P/B Ratio (Annual)3.21x

Inventory Turnover (TTM)18.58x

Pretax Margin (TTM)21.93%

Book Value / Share (Annual)$94.89

Price vs S&P 500 (13W)32.78%

Net Margin Growth (5Y)-11.26%

Beta0.68x

P/FCF (Annual)20.09x

Revenue / Share (TTM)$66.94

ROE (TTM)13.56%

52-Week Low$1512.00

vGradeD

gGradeC

mGradeA

vgmGradeC

GMAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.33	$0.49	+47.50%(+$0.16)
Q1 2026	May 7, 2026	$0.19	$0.13	-29.74%(-$0.06)
Q4 2025	Feb 17, 2026	$0.37	$0.21	-44.55%(-$0.16)
Q3 2025	Nov 6, 2025	$0.45	$0.65	+42.31%(+$0.19)
Q2 2025	Aug 7, 2025	$0.34	$0.54	+61.37%(+$0.21)

GMAB Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.84

3.88

3.92

3.89

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company developing antibody therapeutics for cancer treatment, leveraging proprietary platforms including DuoBody, HexaBody, and DuoHexaBody. The company has a portfolio of approved products including Darzalex (the standard of care for multiple myeloma), Tepezza, Kesimpta, and others developed through strategic partnerships with major pharmaceutical companies. Genmab maintains a pipeline of candidates targeting additional oncologic indications.